Molecular Analysis of Thyroid Tumors

被引:79
作者
Bhaijee, Feriyl [2 ]
Nikiforov, Yuri E. [1 ,3 ]
机构
[1] Univ Pittsburgh, Dept Pathol, UPMC Presbyterian, Pittsburgh, PA 15213 USA
[2] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA
[3] Univ Pittsburgh, Med Ctr, Dept Pathol & Lab Med, Pittsburgh, PA USA
关键词
Thyroid cancer; Papillary carcinoma; Follicular carcinoma; Mutations; Genetic; Molecular; BRAF; RET/PTC; RAS; PAX8/PPAR gamma; NEEDLE-ASPIRATION DIAGNOSIS; REQUIRING REOPERATIVE SURGERY; RET/PTC GENE REARRANGEMENTS; BRAF V600E MUTATION; N-RAS MUTATION; PAPILLARY CARCINOMAS; BRAF(V600E) MUTATION; ONCOGENE ACTIVATION; CLINICAL-IMPLICATIONS; FOLLICULAR VARIANT;
D O I
10.1007/s12022-011-9170-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid cancer is the most common endocrine malignancy, and its incidence is rising in the USA and other countries. Papillary and follicular thyroid carcinomas are the two most common types of thyroid cancer. Non-overlapping genetic alterations, including BRAF and RAS point mutations, and RET/PTC and PAX8/PPAR gamma rearrangements, are found in more than 70% of papillary and follicular thyroid carcinomas. These represent the most common genetic alterations in thyroid cancer, as well as molecular markers of diagnostic and prognostic significance. The use of these and other emerging molecular markers will likely improve the diagnosis of malignancy in thyroid nodules as well as facilitate more individualized operative and postoperative management. Herein, we provide a brief overview of the common genetic alterations in papillary and follicular thyroid carcinoma and discuss the diagnostic and prognostic significance thereof.
引用
收藏
页码:126 / 133
页数:8
相关论文
共 106 条
[91]  
Tallini G, 1999, LAB INVEST, V79, P547
[92]  
Tallini G, 1998, CLIN CANCER RES, V4, P287
[93]   RET oncogene activation in papillary thyroid carcinoma [J].
Tallini, G ;
Asa, SL .
ADVANCES IN ANATOMIC PATHOLOGY, 2001, 8 (06) :345-354
[94]   BRAF mutations are associated with some histological types of papillary thyroid carcinoma [J].
Trovisco, V ;
de Castro, IV ;
Soares, P ;
Máximo, V ;
Silva, P ;
Magalhaes, J ;
Abrosimov, A ;
Guiu, XM ;
Sobrinho-Simoes, M .
JOURNAL OF PATHOLOGY, 2004, 202 (02) :247-251
[95]   Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma [J].
Vasko, VV ;
Gaudart, J ;
Allasia, C ;
Savchenko, V ;
Di Cristofaro, J ;
Saji, M ;
Ringel, MD ;
De Micco, C .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (06) :779-786
[96]  
VIGLIETTO G, 1995, ONCOGENE, V11, P1207
[97]   LOW-FREQUENCY OF REARRANGEMENTS OF THE RET AND TRK PROTOONCOGENES IN JAPANESE THYROID PAPILLARY CARCINOMAS [J].
WAJJWALKU, W ;
NAKAMURA, S ;
HASEGAWA, Y ;
MIYAZAKI, K ;
SATOH, Y ;
FUNAHASHI, H ;
MATSUYAMA, M ;
TAKAHASHI, M .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (07) :671-675
[98]   Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF [J].
Wan, PTC ;
Garnett, MJ ;
Roe, SM ;
Lee, S ;
Niculescu-Duvaz, D ;
Good, VM ;
Jones, CM ;
Marshall, CJ ;
Springer, CJ ;
Barford, D ;
Marais, R .
CELL, 2004, 116 (06) :855-867
[99]   BRAF mutation in thyroid cancer [J].
Xing, M .
ENDOCRINE-RELATED CANCER, 2005, 12 (02) :245-262
[100]  
XING M, 2009, J CLIN ENDOCR METAB, V93, P3943